109 related articles for article (PubMed ID: 6253707)
1. Serum levels of fibronectin and a fibronectin-like DNA-binding protein in patients with various diseases.
Todd HD; Coffee MS; Waalkes TP; Abeloff MD; Parsons RG
J Natl Cancer Inst; 1980 Nov; 65(5):901-4. PubMed ID: 6253707
[TBL] [Abstract][Full Text] [Related]
2. Isolation and identification of a human serum fibronectin-like protein elevated during malignant disease.
Parsons RG; Todd HD; Kowal R
Cancer Res; 1979 Nov; 39(11):4341-5. PubMed ID: 115574
[TBL] [Abstract][Full Text] [Related]
3. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
[TBL] [Abstract][Full Text] [Related]
4. Detection of a human serum DNA-binding protein associated with malignant disease.
Parsons RG; Aldenderfer PH; Kowal R
J Natl Cancer Inst; 1979 Jul; 63(1):43-7. PubMed ID: 221718
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of a 21-kDa protein in the circulation of tumor-bearing patients.
Shalitin C; Epelbaum R; Moskovitz B; Segal R; Valansi C; Werner M; Livne PM
Cancer Detect Prev; 1994; 18(5):357-65. PubMed ID: 7812982
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
[TBL] [Abstract][Full Text] [Related]
7. Analysis of insulin like growth factor 1 and insulin like growth factor binding protein 3 levels in bronchoalveolar lavage fluid and serum of patients with lung cancer.
Unsal E; Köksal D; Yurdakul AS; Atikcan S; Cinaz P
Respir Med; 2005 May; 99(5):559-65. PubMed ID: 15823452
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic significance of plasmatic concentration of fibronectin in patients with bronchial carcinoma].
Leonardo E; Mancuso M; Sanfilippo B; Dogliotti C; Scagliola D; Oliaro A
Minerva Med; 1985 May; 76(19-20):933-5. PubMed ID: 2987760
[TBL] [Abstract][Full Text] [Related]
9. Plasma fibronectin in mammary and uterine carcinomas.
Potazman JP; le Doussal V; Pouillard J; Jallais L; Labat-Robert J
Clin Physiol Biochem; 1988; 6(1):12-20. PubMed ID: 3359739
[TBL] [Abstract][Full Text] [Related]
10. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
[TBL] [Abstract][Full Text] [Related]
11. The significance of serum CA 125 elevation in malignant and nonmalignant diseases.
Sjövall K; Nilsson B; Einhorn N
Gynecol Oncol; 2002 Apr; 85(1):175-8. PubMed ID: 11925140
[TBL] [Abstract][Full Text] [Related]
12. Pseudouridine determination in blood serum as tumor marker.
Salvatore F; Russo T; Colonna A; Cimino L; Mazzacca G; Cimino F
Cancer Detect Prev; 1983; 6(6):531-6. PubMed ID: 6318996
[TBL] [Abstract][Full Text] [Related]
13. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies.
Karapanagiotou EM; Pelekanou E; Charpidou A; Tsaganos T; Anagnostou V; Plachouras D; Giamarellos-Bourboulis EJ; Syrigos KN
Anticancer Res; 2008; 28(2B):1411-5. PubMed ID: 18505088
[TBL] [Abstract][Full Text] [Related]
14. Increased serum and urinary levels of a parathyroid hormone-related protein COOH terminus in non-small cell lung cancer patients.
Nishigaki Y; Ohsaki Y; Toyoshima E; Kikuchi K
Clin Cancer Res; 1999 Jun; 5(6):1473-81. PubMed ID: 10389935
[TBL] [Abstract][Full Text] [Related]
15. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer.
Takigawa N; Segawa Y; Fujimoto N; Hotta K; Eguchi K
Anticancer Res; 1998; 18(2B):1251-4. PubMed ID: 9615796
[TBL] [Abstract][Full Text] [Related]
16. Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas.
Zhang H; Zhao Q; Chen Y; Wang Y; Gao S; Mao Y; Li M; Peng A; He D; Xiao X
Thorax; 2008 Apr; 63(4):352-9. PubMed ID: 18364444
[TBL] [Abstract][Full Text] [Related]
17. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
18. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.
Wu JT; Erickson AJ; Tsao KC; Wu TL; Sun CF
Ann Clin Lab Sci; 2000 Apr; 30(2):175-8. PubMed ID: 10807161
[TBL] [Abstract][Full Text] [Related]
20. Gc group distributions in patients with cancer.
Hughes NR
J Natl Cancer Inst; 1968 Aug; 41(2):303-11. PubMed ID: 4299536
[No Abstract] [Full Text] [Related]
[Next] [New Search]
